Giovanni Valbusa

Giovanni Valbusa

Auto-generated profile, based on publicly available information

Giovanni Valbusa

Bracco Imaging SpA, Centro Ricerche Bracco, Colleretto Giacosa, TO, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Photoacoustics
Verified
Journal Article
Open access
MCMartina Capozza
Martina Capozza
Francesco BlasiFrancesco Blasi
Francesco Blasi
GVGiovanni Valbusa
Giovanni Valbusa
POPaolo Oliva
Paolo Oliva
CCClaudia Cabella
Claudia Cabella
LPLuisa Poggi
Luisa Poggi
PhotoAcoustic Imaging (PAI) is a biomedical imaging modality currently under evaluation in preclinical and clinical settings. In this work, ICG is coupled to an integrin binding vector (ICG-RGD) to combine the good photoacoustic properties of ICG and the favourable αvβ3-binding capabilities of a small RGD cyclic peptidomimetic. ICG-RGD is characterized in terms of physicochemical properties, biodistribution and imaging performance. Tumor uptake was assessed in subcutaneous xenograft mouse models of human glioblastoma (U-87MG, high αvβ3 expression) and epidermoid carcinoma (A431, low αvβ3 expression). ICG and ICG-RGD showed high PA signal in tumors already after 15 min post-injection. At later time points the signal of ICG rapidly decreased, while ICG-RGD showed sustained uptake in U-87MG but not in A431 tumors, likely due to the integrin-mediated retention of the probe. In conclusion, ICG-RGD is a novel targeted contrast agents for PAI with superior biodistribution, tumor uptake properties and diagnostic value compared to ICG.

28 July 2023 in Investigative Radiology
Verified
Journal Article
Open access
AMAlberto Fringuello Mingo
Alberto Fringuello Mingo
SSSonia Colombo Serra
Sonia Colombo Serra
AMAnna Msc Macula
Anna Msc Macula
DBDavide Bella
Davide Bella
FCFrancesca La Cava
Francesca La Cava
GVGiovanni Msc Valbusa
Giovanni Msc Valbusa
Objectives: Artificial intelligence (AI) methods can be applied to enhance contrast in diagnostic images beyond that attainable with the standard doses of contrast agents (CAs) normally used in the clinic, thus potentially increasing diagnostic power and sensitivity. Deep learning–based AI relies on training data sets, which should be sufficiently large and diverse to effectively adjust network parameters, avoid biases, and enable generalization of the outcome. However, large sets of diagnostic images acquired at doses of CA outside the standard-of-care are not commonly available. Here, we propose a method to generate synthetic data sets to train an “AI agent” designed to amplify the effects of CAs in magnetic resonance (MR) images. The method was fine-tuned and validated in a preclinical study in a murine model of brain glioma, and extended to a large, retrospective clinical human data set. Materials and Methods: A physical model was applied to simulate different levels of MR contrast from a gadolinium-based CA. The simulated data were used to train a neural network that predicts image contrast at higher doses. A preclinical MR study at multiple CA doses in a rat model of glioma was performed to tune model parameters and to assess fidelity of the virtual contrast images against ground-truth MR and histological data. Two different scanners (3 T and 7 T, respectively) were used to assess the effects of field strength. The approach was then applied to a retrospective clinical study comprising 1990 examinations in patients affected by a variety of brain diseases, including glioma, multiple sclerosis, and metastatic cancer. Images were evaluated in terms of contrast-to-noise ratio and lesion-to-brain ratio, and qualitative scores. Results: In the preclinical study, virtual double-dose images showed high degrees of similarity to experimental double-dose images for both peak signal-to-noise ratio and structural similarity index (29.49 dB and 0.914 dB at 7 T, respectively, and 31.32 dB and 0.942 dB at 3 T) and significant improvement over standard contrast dose (ie, 0.1 mmol Gd/kg) images at both field strengths. In the clinical study, contrast-to-noise ratio and lesion-to-brain ratio increased by an average 155% and 34% in virtual contrast images compared with standard-dose images. Blind scoring of AI-enhanced images by 2 neuroradiologists showed significantly better sensitivity to small brain lesions compared with standard-dose images (4.46/5 vs 3.51/5). Conclusions: Synthetic data generated by a physical model of contrast enhancement provided effective training for a deep learning model for contrast amplification. Contrast above that attainable at standard doses of gadolinium-based CA can be generated through this approach, with significant advantages in the detection of small low-enhancing brain lesions.

8 May 2025 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
GVGiovanni Valbusa
Giovanni Valbusa
AMAlberto Fringuello Mingo
Alberto Fringuello Mingo
SSSonia Colombo Serra
Sonia Colombo Serra
Special Article; Authors: G. Valbusa, A. Fringuello Mingo, S. Colombo Serra

26 November 2018 in Journal of Biophotonics
Verified
Journal Article
Closed access
PDF file
GVGiovanni Valbusa
Giovanni Valbusa
MCMartina Capozza
Martina Capozza
CBChiara Brioschi
Chiara Brioschi
Francesco BlasiFrancesco Blasi
Francesco Blasi
SGSimona Ghiani
Simona Ghiani
AMAlessandro Maiocchi
Alessandro Maiocchi

15 July 2024 in arXiv
Verified
Preprint
Open access
PDF file
DBDavide Bianchi
Davide Bianchi
SSSonia Colombo Serra
Sonia Colombo Serra
DEDavide Evangelista
Davide Evangelista
PLPengpeng Luo
Pengpeng Luo
Elena MorottiElena Morotti
Elena Morotti
GVGiovanni Valbusa
Giovanni Valbusa
The adoption of contrast agents in medical imaging protocols is crucial for accurate and timely diagnosis. While highly effective and characterized by an excellent safety profile, the use of contrast agents has its limitation, including rare risk of allergic reactions, potential environmental impact and economic burdens on patients and healthcare systems. In this work, we address the contrast agent reduction (CAR) problem, which involves reducing the administered dosage of contrast agent while preserving the visual enhancement. The current literature on the CAR task is based on deep learning techniques within a fully image processing framework. These techniques digitally simulate high-dose images from images acquired with a low dose of contrast agent. We investigate the feasibility of a ``learned inverse problem'' (LIP) approach, as opposed to the end-to-end paradigm in the state-of-the-art literature. Specifically, we learn the image-to-image operator that maps high-dose images to their corresponding low-dose counterparts, and we frame the CAR task as an inverse problem. We then solve this problem through a regularized optimization reformulation. Regularization methods are well-established mathematical techniques that offer robustness and explainability. Our approach combines these rigorous techniques with cutting-edge deep learning tools. Numerical experiments performed on pre-clinical medical images confirm the effectiveness of this strategy, showing improved stability and accuracy in the simulated high-dose images.

20 September 2025
Verified
Book Chapter
Closed access
PDF file
DEDavide Evangelista
Davide Evangelista
Elena MorottiElena Morotti
Elena Morotti
SSSonia Colombo Serra
Sonia Colombo Serra
PLPengpeng Luo
Pengpeng Luo
GVGiovanni Valbusa
Giovanni Valbusa
DBDavide Bianchi
Davide Bianchi